New data on the effects of TG lowering on plaque progression and the longer term use of plozasiran on TG levels were reported at this year’s American College of Cardiology congress in New Orleans, USA (28-30 March 2026). In addition, there were fresh insights on combined olezarsen and fibrate use in TG lowering, and the impact of highest TG levels on CV risk and acute pancreatitis, together with evidence of the value of TG/HDL-C ratio in predicting 30-year CVD risk in women.
Read the reports:
- Essence-TIMI 73b shows no effect of TG lowering on plaque progression at 12 months
- Robust TG lowering with plozasiran across HTG spectrum
- Impact of fibrates on TG lowering with olezarsen
- New insights on impact of highest TG levels
- TG/HDL-C ratio predicts long term CVD risk in women
Reporting by Jenny Bryan
